[{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"The Hospital of Vestfold","sponsor":"South-Eastern Norway Regional Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"NORWAY","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase II","graph3":"The Hospital of Vestfold","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Hospital of Vestfold \/ South-Eastern Norway Regional Health Authority","highestDevelopmentStatusID":"8","companyTruncated":"The Hospital of Vestfold \/ South-Eastern Norway Regional Health Authority"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Gel","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Silodosin","moa":"Adrenergic receptor alpha-1||Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Watson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Watson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Watson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Watson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"GTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor||Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"GTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"GTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GTx \/ Undisclosed"},{"orgOrder":0,"company":"GTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Urology","graph2":"Phase II","graph3":"GTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GTx \/ Undisclosed"},{"orgOrder":0,"company":"GTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Urology","graph2":"Phase II","graph3":"GTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GTx \/ Undisclosed"},{"orgOrder":0,"company":"GTx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen Receptor","graph1":"Urology","graph2":"Phase II","graph3":"GTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GTx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GTx \/ Undisclosed"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"OPK-88004","moa":"Androgen Receptor","graph1":"Urology","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Urology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SK-1404","moa":"AVPR2","graph1":"Urology","graph2":"Phase II","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Il-Yang Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Il-Yang Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Il-Yang Pharm"},{"orgOrder":0,"company":"Southern Illinois University","sponsor":"Astellas Pharma | Sisters of the Third Order of St. Francis","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Southern Illinois University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Southern Illinois University \/ Astellas Pharma | Sisters of the Third Order of St. Francis","highestDevelopmentStatusID":"8","companyTruncated":"Southern Illinois University \/ Astellas Pharma | Sisters of the Third Order of St. Francis"},{"orgOrder":0,"company":"Velicept Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Solabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Velicept Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Velicept Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Velicept Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Velicept Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Solabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Velicept Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Velicept Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Velicept Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Velicept Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Solabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Velicept Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Velicept Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Velicept Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vibegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"JNJ-42160443","moa":"Beta-nerve growth factor","graph1":"Urology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"LP-10","moa":"Calcineurin phosphatase","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide","graph1":"Urology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Calcium-activated potassium channel KCa1.1 (KCNMA1)","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TAC-302","moa":"Cholinergic system","graph1":"Urology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"AGN-214868","moa":"enzymes","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY500307","moa":"Estrogen receptor beta","graph1":"Urology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ASP3652","moa":"FAAH","graph1":"Urology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ASP3652","moa":"FAAH","graph1":"Urology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein-1A","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Antev","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Teverelix Trifluoroacetate","moa":"GnRH receptor","graph1":"Urology","graph2":"Phase II","graph3":"Antev","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antev \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Antev \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IW-3300","moa":"Guanylate cyclase C","graph1":"Urology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"COLOPLAST AS","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Urology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Columbia University \/ Coloplast AS","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Coloplast AS"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Urology","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase II","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Alberta \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Alberta \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Loyola University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase II","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Loyola University \/ Astellas Pharma"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tarafenacin","moa":"Muscarinic acetylcholine receptor M3","graph1":"Urology","graph2":"Phase II","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tolterodine Tartrate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dexmecamylamine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Urology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TAS-303","moa":"Noradrenaline reuptake","graph1":"Urology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TAS-303","moa":"Noradrenaline reuptake","graph1":"Urology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"TAS-303","moa":"Noradrenaline reuptake","graph1":"Urology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taiho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eliapixant","moa":"P2RX3||P2X3","graph1":"Urology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Urology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"GV1001","moa":"peptides","graph1":"Urology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GemVax & KAEL \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Undisclosed"},{"orgOrder":0,"company":"Aquinox Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AQX-1125","moa":"Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1","graph1":"Urology","graph2":"Phase II","graph3":"Aquinox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquinox Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aquinox Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Urology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Vaneltix Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Hyloris Pharmaceuticals \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Vaneltix Pharma"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0.01,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Vaneltix Pharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Allergan","sponsor":"Taris Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Allergan \/ Taris Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Taris Biomedical"},{"orgOrder":0,"company":"Allergan","sponsor":"Taris Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Allergan \/ Taris Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Taris Biomedical"},{"orgOrder":0,"company":"Allergan","sponsor":"Taris Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Taris Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Taris Biomedical"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Taris Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Taris Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Taris Biomedical"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Urology","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Urology","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Hippocrates Research","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Prulifloxacin","moa":"Topoisomerase IV | Bacterial DNA gyrase","graph1":"Urology","graph2":"Phase II","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Hippocrates Research","highestDevelopmentStatusID":"8","companyTruncated":"Angelini Pharma \/ Hippocrates Research"},{"orgOrder":0,"company":"Urotronic Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Urology","graph2":"Phase II","graph3":"Urotronic Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urotronic Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urotronic Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Wellesley Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Paxerol","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Wellesley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wellesley Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Wellesley Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SagaNatura","sponsor":"Universidad Politecnica de Madrid","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Angelica Archangelica Leaf Etract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"SagaNatura","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SagaNatura \/ Universidad Politecnica de Madrid","highestDevelopmentStatusID":"8","companyTruncated":"SagaNatura \/ Universidad Politecnica de Madrid"},{"orgOrder":0,"company":"American Oriental Bioengineering","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AOBO-001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"American Oriental Bioengineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American Oriental Bioengineering \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American Oriental Bioengineering \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ASP4901","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ASP6294","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ASP8302","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"GCP-Service International","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Muscle Precursor Cell","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Zurich \/ GCP-Service International","highestDevelopmentStatusID":"8","companyTruncated":"University of Zurich \/ GCP-Service International"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Peking University People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EG017","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Peking University People's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Peking University People's Hospital"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"FE 201836","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"William Beaumont Hospitals","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LP-08","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Lipella Pharmaceuticals \/ William Beaumont Hospitals","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ William Beaumont Hospitals"},{"orgOrder":0,"company":"Naturex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NDS-446","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Naturex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naturex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Naturex \/ Undisclosed"},{"orgOrder":0,"company":"Li-Cor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nerindocianine","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Li-Cor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Li-Cor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Li-Cor \/ Undisclosed"},{"orgOrder":0,"company":"Li-Cor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nerindocianine","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Li-Cor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Li-Cor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Li-Cor \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ONO-1110","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ONO-8577","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Graminex LLC","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Pollen Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Graminex LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graminex LLC \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Graminex LLC \/ KGK Science"},{"orgOrder":0,"company":"Light Sciences Oncology","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Talaporfin","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Light Sciences Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Sciences Oncology \/ Mundipharma","highestDevelopmentStatusID":"8","companyTruncated":"Light Sciences Oncology \/ Mundipharma"},{"orgOrder":0,"company":"Urigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"URG101","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Urigen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urigen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Urigen \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"UVT","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Versameb \/ Undisclosed"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"8","companyTruncated":"Versameb \/ Touchlight"},{"orgOrder":0,"company":"Versameb","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versameb \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"Versameb \/ PPD"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VNX001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Vaneltix Pharma \/ Prevail Infoworks","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Prevail Infoworks"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Prevail Infoworks","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VNX001","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Vaneltix Pharma \/ Prevail Infoworks","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Prevail Infoworks"},{"orgOrder":0,"company":"Warner Chilcott Company, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"WC3055","moa":"Undisclosed","graph1":"Urology","graph2":"Phase II","graph3":"Warner Chilcott Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Warner Chilcott Company, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Warner Chilcott Company, LLC \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ONO-1110 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystitis, Interstitial.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 30, 2024

                          Lead Product(s) : ONO-1110

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : LP-10 is an intravesical liposomal formulation of tacrolimus, intended for the treatment of patients suffering from moderate to severe hemorrhagic cystitis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 21, 2024

                          Lead Product(s) : Liposomal Tacrolimus

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : VNX001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystitis, Interstitial.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 01, 2024

                          Lead Product(s) : VNX001

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Prevail Infoworks

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : VMB-100 is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Incontinence, Stress.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 07, 2024

                          Lead Product(s) : VMB-100

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : PPD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Mirabegron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder, Overactive.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 26, 2023

                          Lead Product(s) : Mirabegron

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Il-Yang Pharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Endeavor Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Endeavor Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Urology

                          Study Phase : Phase II

                          Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 02, 2023

                          Lead Product(s) : Adalimumab

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.

                          Product Name : Alenura

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 22, 2023

                          Lead Product(s) : Lidocaine,Heparin Sodium

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Vaneltix Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          April 17, 2023

                          Lead Product(s) : Tacrolimus

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Lipella Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Intuitive Surgical

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Intuitive Surgical

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : IS-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ureteral Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 15, 2023

                          Lead Product(s) : IS-001

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : IW-3300 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystitis, Interstitial.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 22, 2023

                          Lead Product(s) : IW-3300

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank